Aclaris Therapeutics
ACRS
98 hedge funds and large institutions have $67.8M invested in Aclaris Therapeutics in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 27 increasing their positions, 39 reducing their positions, and 27 closing their positions.
9% more capital invested
Capital invested by funds: $62.4M → $67.8M (+$5.39M)
7.17% less ownership
Funds ownership: 83.94% → 76.77% (-7.2%)
8% less funds holding
Funds holding: 107 → 98 (-9)
19% less call options, than puts
Call options by funds: $76K | Put options by funds: $94K
31% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 39
33% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$10.4M |
| 2 |
D.E. Shaw & Co
New York
|
+$1.6M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$730K |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$680K |
| 5 |
AI
Acuitas Investments
Seattle,
Washington
|
+$551K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.32M |
| 2 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$1.85M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.84M |
| 4 |
Morgan Stanley
New York
|
-$1.74M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.08M |
ACRS Hedge Fund Activity: Q1 2024 in Review
98 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2024, worth a combined $67.8M — up 8.6% from $62.4M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ACRS and 18 opened new positions — a net loss of 9 holders — while 39 trimmed existing stakes and 27 added.
The largest buyer was BML Capital Management, adding an estimated $10.4M. The largest seller was Citadel Advisors, cutting an estimated $5.32M.
- 98 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2024, down from 107 in Q4 2023.
- Funds reported $67.8M of Aclaris Therapeutics stock for Q1 2024, up 8.6% quarter-over-quarter.
- 18 funds opened new Aclaris Therapeutics positions in Q1 2024 and 27 closed out, a net change of -9 holders.
- The largest Aclaris Therapeutics buyer in Q1 2024 was BML Capital Management, an estimated $10.4M added.
- The largest Aclaris Therapeutics seller in Q1 2024 was Citadel Advisors, an estimated $5.32M sold.
Based on aggregated 13F filings for Q1 2024.